Policy & Regulation
Lytix reports phase II results showing durable responses in advanced melanoma
21 April 2026 - Clinical-stage biotech company Lytix Biopharma ASA (Euronext Growth Oslo:LYTIX) on Tuesday reported final Phase II results for ruxotemitide (LTX-315) in combination with pembrolizumab ...
Rznomics reports RZ-001 interim clinical data in hepatocellular carcinoma at AACR 2026
21 April 2026 - Rznomics Inc, a clinical-stage biopharmaceutical company based in South Korea, announced on Monday the presentation of interim clinical data from its ongoing study of RZ-001, an RNA ed...
Akeso presents positive Phase II results from cadonilimab combination study at AACR 2026
21 April 2026 - Chinese pharmaceutical company Akeso Inc (HK:9926) announced on Monday that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-...
LENZ Therapeutics advances VIZZ regulatory expansion with UK submission for presbyopia treatment
20 April 2026 - US pharmaceutical company LENZ Therapeutics Inc (Nasdaq:LENZ) announced on Monday that it has submitted a marketing authorisation application (MAA) to the United Kingdom's Medicin...
GSK secures China approval for Blenrep in relapsed multiple myeloma
20 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) declared on Monday that it has received approval from China's National Medical Products Administration for Blenrep (belant...
Sanofi's Nuvaxovid demonstrates superior tolerability to Moderna's mNEXSPIKE in phase 4 study
20 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Saturday that its protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2705), showed statistically sig...